|
Investors
Historically, Inotek has pursued a unique funding strategy. From 1997-2004, the Company was highly effective in attracting non-dilutive funding totaling over $50 million through federal and private grants and contracts. Since 2004, Inotek has been successful in raising additional equity capital with funding from top tier biotechnology and pharmaceutical investors. In February of 2004, Inotek completed a $20 million round of Series A private equity financing. In October of 2005, the Company raised an additional $35 million in a Series B round. Inotek completed a Series C financing round in the amount of $24 million, which closed in October of 2007. In June 2010, Inotek closed a preferred stock financing in the amount of $18 million.
Inotek's current investors include the following:
-
Devon Park Bioventures - Devon Park Bioventures is a venture capital fund targeting investments in therapeutics companies and, in certain cases, medical device, diagnostic and drug discovery technology companies.
-
Care Capital LLC - Care Capital is an investment firm focusing on opportunities in life sciences, particularly companies developing pharmaceuticals.
-
Rho Ventures - Rho Ventures is a venture capital firm with extensive investments in the healthcare, information technology, and communications sectors.
-
MedImmune Ventures - MedImmune Ventures is a wholly owned venture capital subsidiary of MedImmune, Inc., a leading biotechnology company. MedImmune Ventures seeks to discover and invest in companies and organizations developing therapeutic products or technologies with significant potential to improve the treatment or prevention of human disease.
-
Pitango Venture Capital - Pitango Venture Capital is Israel's largest venture capital firm and a lead investor in seed, early, and expansion stage companies. Pitango has helped grow over 100 companies, managing funds in excess of $1 billion in committed capital.
-
Caisse de dépôt et placement du Québec - The Caisse de dépôt et placement du Québec ("the Caisse") is a financial institution that manages funds primarily for public and private pension and insurance funds. As of December 31, 2004, it held CA$102.4 billion of net assets. The Caisse invests in the main financial markets as well as in private equity and real estate. As of December 31, 2004, the private equity portfolios held more than 600 investments in funds and companies, totalling CA$10.2 billion in net assets.
-
Hercules Technology Growth Capital, Inc. (HTGC) - Hercules Technology Growth Capital, Inc. is a NASDAQ traded specialty finance company providing debt and equity growth capital to technology and life science companies at all stages of development. Founded in December 2003, the company primarily finances privately held companies backed by leading venture capital and private equity firms. Hercules invests in a broad range of ventures active in technology and life science industries and offers a full suite of growth capital products up and down the capital structure. The company is headquartered in Palo Alto, Calif. and has additional offices in the Boston, Boulder, San Diego and Chicago areas. Providing capital to publicly-traded or privately-held companies backed by leading venture capital and private equity firms involves a high degree of credit risk and may result in potential losses of capital.
-
Mitsubishi UFJ Capital Co. - Mitsubishi UFJ Capital Co., Ltd is an investment firm that was formed on October 1, 2005 by the merger of Diamond Capital and UFJ Capital and has financed more than 1,000 companies of which more than 290 have gone public. The Company invests in multiple sectors with an increasing focus on Healthcare, Biotech, IT, Electronics, and High Technology. Investments are focused domestically with selective cross border investments. The Company works with local venture capital investment partners to increase cross-border deal flow. Mitsubishi UFJ Capital brings unrivalled insight and access to overseas companies and investors targeting the Japanese market.
-
Bio*One Capital Pte Ltd - Bio*One Capital Pte Ltd is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. With funds of over S$600 million, investments are focused on promising and innovative global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies’ growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 60 companies in the US, Europe, Singapore and Asia.
(Click on name above to link to the investor's corporate website. By clicking on these links, the user understands that he/she is leaving Inotek Pharmaceuticals Corporation's website.)
This page contains forward-looking statements. Such statements are subject to certain factors which may cause Inotek's plans to differ or results to vary from those expected, including the results of pre-clinical or clinical studies (including termination or delay in clinical programs or inability to move forward to the next Phase of clinical development), the need for additional research and testing, delays in developing or arranging satisfactory manufacturing capability, inability to access capital and funding on a timely basis and on favorable terms, delays in development of or adverse changes in status of commercial relationships, the possibility that favorable results of earlier clinical trials are not predictive of safety and efficacy results in later clinical trials, dependence on strategic partners for performance of development and commercial matters, the risk that third parties won't agree to license us on reasonable terms their intellectual property necessary for us to develop and commercialize our products, and a variety of other risks.
|
